GSK shares fall 6% after scope narrowed for leading vaccine
US Centre for Disease Control restricts vaccine useDecision could limit vaccine salesGSK has a leading market share in RSV vaccinesShares in GSK (GSK) were marked down 5% to £15.16 after the US CDC (Centre for Disease Control) advised a narrower use of RSV (respiratory syncytial virus) vaccines, cutting the potential market for GSK's leading Arexvy vaccine.The drop eradicates most the year's gain